Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of thoracic oncology 2014-12, Vol.9 (12), p.e86-e87
Hauptverfasser:	Toyokawa, Gouji, Hirai, Fumihiko, Inamasu, Eiko, Yoshida, Tsukihisa, Nosaki, Kaname, Takenaka, Tomoyoshi, Yamaguchi, Masafumi, Seto, Takashi, Takenoyama, Mitsuhiro, Ichinose, Yukito
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Bone Neoplasms - drug therapy Bone Neoplasms - secondary Brain Neoplasms - drug therapy Brain Neoplasms - secondary Carbazoles - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - pathology Clinical Trials, Phase III as Topic Drug Resistance, Multiple Female Gene Fusion Humans Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - pathology Mutation Piperidines - therapeutic use Protein Kinase Inhibitors - therapeutic use Pyrazoles - therapeutic use Pyridines - therapeutic use Randomized Controlled Trials as Topic Receptor Protein-Tyrosine Kinases - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!